|
|
||||||||
1 From the Southampton Eye Unit; and the 2 Departments of Pathology and 3 Immunopharmacology, Southampton University, Hampshire, United Kingdom.
| Abstract |
|---|
|
|
|---|
METHODS. Sequential and double in situ hybridization (ISH) and immunohistochemistry (IHC) were performed on thin sections of human conjunctiva to determine the colocalization of the immunoreactivity of IL-4, IL-5, IL-6, and IL-13 to mast cell subsets in normal subjects and subjects with atopy and to detect IL-4 mRNA in conjunctival mast cells.
RESULTS. More than 90% of IL-4+immunoreactive cells were observed to be mast cells in conjunctival biopsy specimens from all patient groups. The majority of IL-5+, IL-6+, and IL-13+ cells were also noted to be mast cells for each group. IL-4 preferentially colocalized to the tryptase+-chymase+ mast cell phenotype (MCTC) with MCTC cells comprising 93.3% of cytokine+ mast cells in symptomatic SAC (P = 0.0017), 89.2% in asymptomatic SAC (P = 0.0008), and 77.8% in normal subjects (P = 0.0472). IL-13 appeared to colocalize preferentially to the MCTC phenotype and IL-5 and IL-6 to the MCT phenotype. ISH showed that 75.8% of mast cells in normal subjects, 78.7% in subjects with symptomatic SAC, and 18.7% in subjects with asymptomatic SAC expressed mRNA for IL-4.
CONCLUSIONS. Conjunctival mast cells are an important source of IL-4, IL-5, IL-6, and IL-13 immunoreactivity, with preferential colocalization of IL-4 and IL-13 on the MCTC subset and IL-5 and IL-6 to the MCT subset. This evidence suggests that differences in protease phenotype may also reflect functional differences evidenced by the different patterns of cytokine distribution.
| Introduction |
|---|
|
|
|---|
In the present study, we sought to investigate the normal pattern of cytokine expression between MCT and MCTC subsets. To explore changes during natural allergen exposure, we studied patients with SAC who were asymptomatic or symptomatic, with regard to itch, and compared them with normal control subjects. In addition, we sought evidence that conjunctival mast cells are capable of sustained cytokine production through the synthesis of IL-4 mRNA.
| Materials and Methods |
|---|
|
|
|---|
Conjunctival Biopsy and Tissue Fixation and Processing
We chose to obtain biopsy specimens from bulbar conjunctiva,
because the procedure is less traumatic than tarsal biopsy and is
consistent with our previous reports on conjunctival pathophysiology.
Our previous work20
and that of others21
has
also demonstrated similar numbers of inflammatory cells at both sites,
typically with slightly higher numbers of mast cells in bulbar tissue,
and similar correlations between adhesion molecule expression and
inflammatory cells at both sites. Lastly, sampling error was thought
likely to be similar for a small sample of tissue taken from one site
at one time compared with examining the entire conjunctiva.
After instillation of topical oxybuprocaine (Chauvin Pharmaceuticals, Romford, UK), a snip biopsy was performed in the upper bulbar conjunctiva. Specimens were divided into two pieces, one sample processed for IHC and the other for ISH. Tissue samples for IHC were immersed immediately into chilled acetone containing protease inhibitors (2 mM phenylmethylsulfonyl fluoride and 20 mM iodoacetamide) and stored overnight at -20°C. They were then processed into a water-soluble resin, glycol methacrylate (GMA), as described previously.22 The blocks were polymerized overnight at 4°C and stored at -20°C in airtight containers containing silica resin. Samples for ISH were immersed in 10% neutral buffered formalin for overnight fixation and processed into paraffin wax using an automatic processor (Hypercentre 2; Shandon, Cheshire, UK).
Antibody and Riboprobe Sources
The following monoclonal antibodies (mAbs) were obtained from
the following sources: AA1, Andrew F. Walls (Clinical
Pharmacology, Southampton University, UK); MAB1254, Chemicon (Harrow,
UK); 3H4 and 4D9, Christophe Heusser (CibaGeigy, Basel, Switzerland);
MAB7, Laurie McNamee (Glaxo SmithKline, Oxbridge, UK); 104B11, Paul
Hissey (Glaxo SmithKline); MAB 213, R&D Systems (Oxford, UK); UCHT1,
Dako (High Wycombe, UK); M9269, Sigma (Poole, UK);
streptavidin-biotin-peroxidase complexes (SBP), Dako; fluorescein
isothiocyanate (FITC) anti-mouse, Dako; and anti-digoxigenin antibody,
BoehringerMannheim (East Sussex, UK).
In Situ Hybridization
IHC was performed as previously described.3
Two-micrometer-thick sections were cut, floated onto 0.2% ammonia
water, and picked up on poly-L-lysinecoated slides.
Endogenous peroxidase activity was blocked by treatment with sodium
azide 0.1% wt/vol and hydrogen peroxide 0.003% vol/vol. Nonspecific
binding sites were blocked by incubation in tissue culture medium
(Dulbeccos modified Eagles medium and 20% fetal calf serum).
Primary antibodies were applied overnight at room temperature. The
following mouse IgG1 mAbs were used at previously
titrated optimal dilutions: AA1 to mast cell tryptase, MAB1254 to mast
cell chymase, MAB7 to IL-5, 104B11 to IL-6, MAB 213 to IL-13, and UCHT1
to CD3. Two different mAbs to IL-4 were used, 3H4 and 4D9. 3H4
typically gives a ring staining pattern, suggesting detection of IL-4
epitopes expressed when the cytokine is at the cell surface, 4D9 gives
a principally cytoplasmic staining pattern suggestive of stored
IL-4.12
We used both mAbs, because our previous studies on
the upper airway mucosa and conjunctiva had shown differences between
IL-4 expression with regard to surface compared with stored
IL-4.13
18
Control slides included omission of the primary
antibody, and because all other mAbs were IgG, a nonspecific
IgG1 mAb at the highest concentration for a
primary antibody was also used (M9269). The absence of
IgG1 cross-reactivity was confirmed by
preliminary experiments using an additional biotin-blocking stage after
ISH, which showed no difference in staining quality between sections
processed with or without this stage. After incubation with
biotinylated second-stage antibodies (Dako), detection was achieved
with streptavidin-biotin-peroxidase complexes (SBP), using
aminoethylcarbazole to obtain a red reaction product.
Double IHC
Four-micrometer-thick sections were cut and treated as for
standard IHC. Primary antibodies to mast cell tryptase (AA1) and IL-4
(3H4) were applied as before and labeled with either SBP with fast red
as a chromogen or FITC anti-mouse mAb. Propidium iodide was used as a
counterstain and the cells detected using a confocal laser microscope
(Leica, Cambridge, UK). Stringent controls were performed to ensure the
specificity of the detection, with the omission of each primary
antibody and, separately, the omission of each secondary antibody,
followed by application of both detection systems.
IL-4 Riboprobe Synthesis
A 0.3-kb human IL-4 cDNA insert from recombinant pUC18 (R&D
Systems) was excised and subcloned into pSP70 (Promega, Southampton,
UK) in its multiple cloning site based on the human IL-4 gene nucleic
acid sequence published by Yokata.23
The insert was
oriented so that T7 promoter conduction would yield an antisense RNA
transcript. HindIII or EcoRI digestion was then
used to linearize the recombinant pSP70 IL-4. Digoxigenin-labeled
antisense cDNA probe for IL-4 was synthesized by in vitro transcription
(BoehringerMannheim) using 1 µg of HindIII-linearized
pSP70 IL-4, 20 nanomoles of digoxigenin-uridine triphosphate, and 20 U
of T7 RNA polymerase at 37°C. A sense IL-4 RNA probe was generated
using the EcoRI digest of pSP70 IL-4 by SP6 RNA
polymeraseconducted transcription. The synthesized RNA transcripts
were checked by agarose gel electrophoresis to confirm a 300-bp
fragment. The digoxigenin labeling of each RNA probe produced was
confirmed by dot-blot immunostaining with anti-digoxigenin antibody
(BoehringerMannheim).
Immunohistochemistry
ISH was performed as previously described.24
Conjunctival biopsy specimens were fixed by overnight immersion in 10%
neutral buffered formalin and processed as before.
Four-micrometer-thick sections were cut, floated onto a water bath at
37°C, and picked up on aminopropyl-triethoxysilane coated slides.
Sections were dewaxed, rehydrated, and washed in diethylpyrocarbonate
(DEPC)treated water followed by immersion in 0.2 N HCl at room
temperature. The sections were then transferred to preheated (70°C)
SSC and washed before buffering in 50 mM Tris/HCl. Permeabilization was
performed by proteinase K (Sigma) treatment at 5 µg/ml at 37°C.
Posttreatment fixation was achieved by immersion in 0.4%
paraformaldehyde at 4°C. Before the hybridization of probe to target
mRNA, the sections were incubated in the hybridization buffer. Fresh
hybridization buffer was then added with digoxigenin-labeled antisense
riboprobe at a final concentration of 5 ng/µl at 42°C overnight.
Nonspecifically bound probe was removed by stringent washing using
progressively decreasing salt concentrations of SSC at 42°C with the
addition of formamide (30%) to the last wash. Nonspecific
antibody-binding slides were blocked by washing in 3% bovine serum
albumin (BSA)/0.1% Triton X-100 in Tris-buffered saline (TBS). Probe
detection was achieved using antidigoxigenin alkaline
phosphataseconjugated antibody at 1:600 (Sigma) in TBS. Bound
antibody was detected by characteristic blue-black staining with the
chromogen nitrobluetetrazolium-5 bromo-4 chloro-3 indolyl phosphate
(NBT-BCIP; Sigma). Negative control slides were produced using the
sense IL-4 riboprobe and omission of riboprobe. Positive controls were
performed using a 300-bp riboprobe for the constitutive cytoskeletal
protein ß-actin (Ambion, Oxford, UK).
Double ISH-IHC
The ISH protocol was followed by IHC, using the mAb AA1 to mast
cell tryptase as described earlier. Control slides were treated
identically and comprised a combination of sense probe and irrelevant
antibody controls performed as part of the individual protocols for IHC
and ISH.
Quantification and Statistical Analysis
Cells were counted without knowledge of their original source.
Only nucleated cells were counted, and all cells within each specimen
were counted at a magnification of x400. To measure counting
consistency, 20% of the slides were re-counted by the same observer,
who was masked to the specimen number and group from which the
slides were chosen. The area of lamina propria (in square
millimeters) and length of the epithelium (in millimeters) was measured
using a semiautomated image analysis system (Colorvision 1.7.4a;
ImproVision, Warwick, UK; and Symantec, Cupertino, CA.). Using
the method of Bland and Altman,25
a coefficient of
repeatability (twice the SD of the log-transformed differences in
counts) was calculated for the recounted slides.
Tryptase+ and/or chymase+ cells showed colocalized positivity to both the 3H4 or 4D9 mAbs for IL-4 and for IL-5, IL-6, and IL-13 by using a camera lucida to identify the same cells in adjacent sections. In addition, IL-4 was colocalized to CD3+ cells by using the 3H4 and 4D9 IL-4 mAbs and UCHT1 (CD3) mAb. Three random microscope fields with high cell counts were examined at x250 magnification. In cases in which immunoreactivity of positive granules could not be shown to colocalize on nucleated cells (Fig. 1C ), the cells were not counted. Sections processed for double ISH-IHC were counted at a magnification of x400, and the number of cells positive for IL-4 mRNA, tryptase, and both IL-4 mRNA and tryptase was noted.
|
| Results |
|---|
|
|
|---|
Clear immunohistochemical staining for IL-4, IL-5, IL-6, IL-13, mast cell tryptase and chymase, and CD3+ T cells was observed, with no staining appearing on the control slides. Examination of sequential sections using morphologic landmarks to orient the specimen under the microscope enabled the identification of the same cells and the colocalization of cytokine product to mast cell subtypes (Figs. 1A 1B 1C) .
The mAb 3H4 to IL-4 gave predominantly a ring staining pattern (Fig. 1B) , although cytoplasmic staining was observed in a significant proportion of cells. This pattern was also imaged by double immunofluorescence confocal microscopy, which clearly demonstrated 3H4+ staining at the mast cell surface (Fig. 1E) . Staining with the mAb 4D9 to IL-4 resulted in predominantly cytoplasmic staining, although ring staining was noted in a few cells. Immunostaining for IL-5, IL-6, and IL-13 was cytoplasmic, with very few cells displaying surface staining. Mast cells were observed to stain for both 3H4 and 4D9 mAbs in sequential sections. Although 3H4+ mast cells were often positive for both 3H4 and 4D9 epitopes of IL-4, this was not always the case. 4D9+ mast cells were not always 3H4+, although the numbers in each group were too small to achieve a statistically significant comparison. In sequential sections from two biopsy specimens, one from a normal subject and one from a symptomatic patient, some mast cells were observed to be positive for IL-4, IL-5, and IL-6. No CD3+ cells were noted to show colocalization of either 3H4 or 4D9 immunoreactivity. Because CD3+ cells are recognized as an important source of cytokines in allergic diseases, it is possible that the failure of cytokine product to colocalize on these cells was due to the rapid export of cytokine from the cell with insufficient cytokine epitope available for immunodetection. Mast cells were predominantly located subepithelially and around blood vessels, with no mast cells noted in the epithelium in control specimens or in those from asymptomatic subjects. Two intraepithelial mast cells were observed in two symptomatic patients with SAC. Although the large majority of chymase+ cells were also tryptase+, some chymase+ cytokine+-only cells were observed.
Leukocyte and Cytokine Counts
Mast cell numbers were elevated in symptomatic patients with SAC
(27.6 ± 3.9/mm2) compared with asymptomatic
(24.1 ± 3.3/mm2) and normal subjects
(18.6 ± 2.2/mm2; Fig. 2
), although the difference did not reach statistical significance.
Epithelial CD3+ cell numbers were noted to be
significantly higher in symptomatic patients (64.9 ±
12.0/mm2) than in asymptomatic patients
(13.6 ± 6.3/mm2, P = 0.014) and
normal control subjects (26.9 ± 6.6 mm2,
P = 0.03). CD3+ cell numbers in the
substantia propria were also significantly higher in symptomatic
patients (66.9 ± 20.3/mm2) than in
asymptomatic patients (9.0 ± 2.8/mm2,
P = 0.0019; Fig. 2
) but not normal subjects (27.7 ±
6.8/mm2, P = nonsignificant [ns]).
Although mean epithelial and substantia propria
CD3+ cell numbers were almost double in normal
control subjects compared with asymptomatic patients, these differences
were not statistically significant, probably because of the data
variation.
|
The large majority of cytokine+ cells were mast cells (Fig. 3) . This was most marked for IL-4, with which more than 90% of 4D9+ and 80% of 3H4+ immunoreactivity was observed in tryptase+ cells, irrespective of group of origin. For IL-5, IL-6 , and IL-13, the majority of cytokine+ cells were also noted to be tryptase+, irrespective of group of origin (Fig. 3) . We did not seek to identify the minority of cytokine+ positive cells that were, by exclusion, neither mast cells nor CD3+ cells. No significant differences in the proportion of cytokine+ mast cells were found between the disease groups and the control group.
|
IL-4+ mast cells displayed clear phenotypic heterogeneity. Surface 3H4+ immunoreactivity colocalized significantly to MCTC cells in symptomatic (P = 0.0008) and asymptomatic (P = 0.006) subjects with SAC (normal subjects, P = ns; Fig. 4A ), whereas 4D9+ immunoreactivity colocalized significantly to MCTC cells in all groups (normal tissue, P = 0.0472; symptomatic SAC, P = 0.0017; asymptomatic SAC, P = 0.0008; Fig. 4B ). A less consistent pattern was observed for IL-13+ mast cells, with the greatest difference noted in asymptomatic SAC (P = ns; Fig. 5 ). IL-5+ and IL-6+ immunoreactivities were variable but appeared to colocalize preferentially to MCT cells, except for IL-5+ mast cells in subjects with asymptomatic SAC (Fig. 5) . The differences in distribution did not achieve statistical significance.
|
|
| Discussion |
|---|
|
|
|---|
Our observation of an increase in mast cell numbers during active disease was consistent with our earlier reports3 18 26 and with their known role in SAC.1 2 The increases in CD3+ cell number in both the substantia propria and epithelium were also consistent with the observation of increased expression of the adhesion proteins intracellular adhesion molecule-1 (CD54) and vascular cell adhesion molecule-1 (CD106) whose ligands are found on T cells and granulocytes in conjunctival biopsy specimens from patients with allergic conjunctivitis.20
Although T cells are known to be an important source of cytokines in allergic diseases, they require activation and, in the case of TH2-like cells, priming with IL-4 before they can release it.27 We observed mast cells to be the source of the large majority of IL-4, IL-5, IL-6, and IL-13 immunoreactivity, irrespective of the group from which the tissue was obtained. Because these cytokines appeared to be stored within the cytoplasmic secretory granules, it is likely that they are released during IgE-mediated stimulation, resulting in a rapid pulse of these immunomodulatory proteins into the surrounding microenvironment. By demonstrating that the large majority of IL-4+ immunoreactivity and IL-4 mRNA in normal human conjunctival tissue was localized to mast cells, these results also suggest that this cell is capable of sustained IL-4 production. The presence of IL-4 was confirmed, not just by the colocalization of 3H4 and 4D9 immunoreactivity to both MCT and MCTC phenotypes in serial sections, but also by double IHC, which demonstrated simultaneous expression of IL-4 and the unique mast cell protease marker tryptase in the same cells. In contrast, no IL-4 product colocalized to CD3+ cells, perhaps because these cells do not have the necessary structures to store sufficient cytokine for immunodetection.
We noted that IL-4 and IL-13 colocalized preferentially to the
MCTC subset in disease and control groups.
Because IL-4 is well recognized to upregulate humoral and suppress
cell-mediated immunity by stimulating the differentiation of the
TH2 subset of T-helper cell,27
this
evidence suggests that MCTC cells are capable of
participating in the local regulation of IgE. It is known that mast
cells can induce B-cell isotype switching to IgE synthesis through
direct CD40/CD40 ligand binding and through the release of IL-4 and
IL-13 independent of T-cell help.28
IL-4 has also been
shown to upregulate the high-affinity IgE receptor component,
Fc
RI
chain, on human mast cells.29
IL-5 and IL-6
appeared to colocalize to the MCT subset although
the difference in distribution was less marked, and IL-5 and IL-6 cell
counts were low in all groups including symptomatic patients. Because
MCT cells remained in the minority among mast
cells in all groups, the low levels of IL-5 and IL-6 immunoreactivity
appeared to be consistent with the mild nature of SAC compared with
chronic allergic eye diseases in which IL-5driven eosinophil
activation plays a central role.
The preferential distribution of TH2-like cytokine immunoreactivity between MCTC and MCT cells observed in this study supports the hypothesis that these subsets may play different roles during physiological or pathologic conditions. Both 3H4 and 4D9 mAbs to IL-4 displayed a significant preferential colocalization to the MCTC subset. The ring staining pattern observed with mAb 3H4 may have reflected cell surface cytokine possibly in the process of release. This would be in agreement with the observed increase in 3H4+ cells in symptomatic patients compared with control subjects. The number of cytoplasmic 4D9+ cells declined in symptomatic patients compared with numbers in both asymptomatic and normal control subjects, consistent with cytokine depletion during degranulation. It is possible that the 3H4 staining reflected IL-4 bound to the IL-4 receptor (IL-4R) at the cell surface, but the absence of immunoreactivity on the surface of other cells known to express the IL-4R made this possibility less likely. The high proportion of mast cells observed to express IL-4 mRNA in conjunctiva taken from symptomatic patients compared with the low proportion in asymptomatic patients suggests that induced transcription of IL-4 mRNA may play an important role in the regulation of IL-4 activity. The relatively high proportion of mast cells positive for IL-4 mRNA in conjunctiva from normal control subjects, however, suggests that cytokine storage and release from mast cell granules could also play a role in cytokine regulation. Clearly, future functional studies are needed to clarify this issue.
The findings that mast cells are an important source of the preformed conjunctival TH2-like cytokines IL-4, IL-5, IL-6, and IL-13 and that the distribution of these cytokines is strongly related to cell phenotype enhances our understanding of the role of the conjunctival mast cell in the local immunoregulation of SAC. As a source of IL-4 and IL-13, these observations provide a potential new mechanism for MCTC cells to bias the conjunctiva toward the development of a TH2-like immune response before IgE-mediated activation. Although the concept of mast cell subsets based on cytokine secretory pattern has yet to be explored, the functional significance of this heterogeneity suggests different roles for MCT and MCTC cells in atopic and nonatopic disorders of the conjunctiva.
| Footnotes |
|---|
Submitted for publication March 24, 2000; revised September 29, 2000; accepted November 2, 2000.
Commercial relationships policy: N.
Corresponding author: David F. Anderson, Southampton Eye Unit, Tremona Road, Southampton, Hampshire SO16 6YD, UK. danders{at}med.miami.edu
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |